Back to top

Fulcrum Therapeutics (FULC) Gets a Hold from Truist Financial

In a report released today, Gregory Renza from Truist Financial maintained a Hold rating on Fulcrum Therapeutics, with a price target of $4.00. Acc...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Fulcrum Therapeutics, Inc. (FULC)